logo-loader
viewHeat Biologics

Heat Biologics forms partnership with Waisman Biomanufacturing to manufacture coronavirus vaccine

Heat Biologics, Inc. (NASDAQ:HTBX) CEO Jeff Wolf tells Proactive the clinical-stage biopharmaceutical company is collaborating with Waisman Biomanufacturing to establish a partnership to manufacture Heat's coronavirus vaccine for expected Phase 1 clinical trials.

Wolf says North Carolina-based Heat has previously worked with Waisman to manufacture Heat's HS-130, which is currently in a Phase 1 clinical trial.

Quick facts: Heat Biologics

Price: 1.28 USD

NASDAQ:HTBX
Market: NASDAQ
Market Cap: $108.38 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Heat Biologics named herein, including the promotion by the Company of Heat Biologics in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Heat Biologics doses first patient in its Phase 1 clinical trial evaluating...

Heat Biologics, Inc subsidiary Pelican Therapeutics CEO Rahul Jasuja tells Proactive the clinical-stage biopharmaceutical company has dosed its first patient in its first-in-human Phase 1 clinical trial evaluating PTX-35 as an anti-cancer drug. Jasuja says this first-in-human study is...

3 weeks ago

2 min read